Crismita Dmello

1.9k total citations · 4 hit papers
32 papers, 974 citations indexed

About

Crismita Dmello is a scholar working on Genetics, Molecular Biology and Cell Biology. According to data from OpenAlex, Crismita Dmello has authored 32 papers receiving a total of 974 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Genetics, 9 papers in Molecular Biology and 9 papers in Cell Biology. Recurrent topics in Crismita Dmello's work include Glioma Diagnosis and Treatment (10 papers), Skin and Cellular Biology Research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Crismita Dmello is often cited by papers focused on Glioma Diagnosis and Treatment (10 papers), Skin and Cellular Biology Research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Crismita Dmello collaborates with scholars based in United States, India and France. Crismita Dmello's co-authors include Prakash Gangadaran, Byeong‐Cheol Ahn, Fatima Khan, Manasi P. Jogalekar, Adam M. Sonabend, Roger Stupp, Víctor A. Arrieta, Catalina Lee-Chang, Milind M. Vaidya and Anshika Goenka and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and PLoS ONE.

In The Last Decade

Crismita Dmello

31 papers receiving 966 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumor microenvironment signaling and therapeutics in cancer progression

2023 154 citations Anshika Goenka, Fatima Khan et al. Cancer Communications profile →
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment

2023 148 citations Víctor A. Arrieta, Crismita Dmello et al. Journal of Clinical Investigation profile →
STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma

2023 139 citations Peng Zhang, Aida Rashidi et al. Nature Communications profile →
CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

2022 122 citations Manasi P. Jogalekar, Ramya Lakshmi Rajendran et al. Frontiers in Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Crismita Dmello United States	12	363	305	291	247	142	32	974
Kenneth C. Valkenburg United States	7	446 1.2×	526 1.7×	313 1.1×	215 0.9×	233 1.6×	8	1.1k
Valentina Mele Switzerland	14	327 0.9×	683 2.2×	218 0.7×	307 1.2×	228 1.6×	30	1.2k
Kunhong Zhong China	15	672 1.9×	638 2.1×	338 1.2×	170 0.7×	85 0.6×	32	1.4k
Yen Phung United States	14	278 0.8×	258 0.8×	169 0.6×	145 0.6×	75 0.5×	15	966
Nuria Mencia-Trinchant United States	14	579 1.6×	222 0.7×	202 0.7×	140 0.6×	288 2.0×	27	1.3k
Simone Gaedicke Germany	18	362 1.0×	497 1.6×	354 1.2×	141 0.6×	137 1.0×	27	1.0k
Edwardine Labay United States	12	540 1.5×	415 1.4×	211 0.7×	167 0.7×	223 1.6×	14	1.1k
Yingjun Su China	10	341 0.9×	382 1.3×	252 0.9×	71 0.3×	109 0.8×	21	900
Pavel Klener Czechia	25	631 1.7×	638 2.1×	266 0.9×	105 0.4×	146 1.0×	121	1.6k

Countries citing papers authored by Crismita Dmello

Since Specialization

Citations

This map shows the geographic impact of Crismita Dmello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Crismita Dmello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Crismita Dmello more than expected).

Fields of papers citing papers by Crismita Dmello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Crismita Dmello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Crismita Dmello. The network helps show where Crismita Dmello may publish in the future.

Co-authorship network of co-authors of Crismita Dmello

This figure shows the co-authorship network connecting the top 25 collaborators of Crismita Dmello. A scholar is included among the top collaborators of Crismita Dmello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Crismita Dmello. Crismita Dmello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fares, Jawad, et al.. (2025). Rethinking metastatic brain cancer as a CNS disease. The Lancet Oncology. 26(2). e111–e121. 1 indexed citations

Ali, Heba, Justin Low, David M. Ashley, et al.. (2025). Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors. Oncotarget. 16(1). 445–453. 1 indexed citations

Lukas, Rimas V., Shashwat Tripathi, Jared T. Ahrendsen, et al.. (2024). Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?. Neuro-Oncology. 27(1). 33–49. 2 indexed citations

Habashy, Karl J., et al.. (2024). Combining causal and correlative approaches to discover biomarkers of response to paclitaxel. Oncotarget. 15(1). 117–122. 1 indexed citations

Dmello, Crismita, Andrew Brenner, David Piccioni, et al.. (2024). Phase II trial of blood–brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma. Neuro-Oncology Advances. 6(1). vdae186–vdae186. 6 indexed citations

Habashy, Karl J., Crismita Dmello, Víctor A. Arrieta, et al.. (2024). Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma. Clinical Cancer Research. 30(8). 1619–1629. 9 indexed citations

Najem, Hinda, Shashwat Tripathi, Lisa Hurley, et al.. (2024). IMMU-19. PRECLINICAL THERAPEUTIC ACTIVITY AND PET IMAGING OF STING AGONIST 8803 IN GLIOBLASTOMA. Neuro-Oncology. 26(Supplement_8). viii156–viii156. 1 indexed citations

Gould, Andrew, Crismita Dmello, Rimas V. Lukas, et al.. (2023). Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas. PubMed. 3(1). 77–86. 8 indexed citations

Goenka, Anshika, Fatima Khan, Priyanka Sinha, et al.. (2023). Tumor microenvironment signaling and therapeutics in cancer progression. Cancer Communications. 43(5). 525–561. 154 indexed citations breakdown →

10.

Fares, Jawad, Crismita Dmello, Peng Zhang, et al.. (2023). Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. Molecular Cancer Research. 21(5). 389–396. 4 indexed citations

11.

Arrieta, Víctor A., Crismita Dmello, Daniel J. McGrail, et al.. (2023). Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment. Journal of Clinical Investigation. 133(2). 148 indexed citations breakdown →

12.

Arrieta, Víctor A., Johnny Duerinck, Kirsten B. Burdett, et al.. (2023). ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis. Clinical Cancer Research. 30(2). 379–388. 6 indexed citations

13.

Zhang, Peng, Aida Rashidi, Junfei Zhao, et al.. (2023). STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nature Communications. 14(1). 1610–1610. 139 indexed citations breakdown →

14.

Jogalekar, Manasi P., Ramya Lakshmi Rajendran, Fatima Khan, et al.. (2022). CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments. Frontiers in Immunology. 13. 925985–925985. 122 indexed citations breakdown →

15.

Dmello, Crismita, et al.. (2021). FKBP1A upregulation correlates with poor prognosis and increased metastatic potential of HNSCC. Cell Biology International. 46(3). 443–453. 9 indexed citations

16.

Zhang, Daniel Y., Andrew Gould, Hannah C. Happ, et al.. (2021). Ultrasound-mediated blood–brain barrier opening increases cell-free DNA in a time-dependent manner. Neuro-Oncology Advances. 3(1). vdab165–vdab165. 10 indexed citations

17.

Zhang, Daniel Y., Crismita Dmello, Li Chen, et al.. (2019). Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations. Clinical Cancer Research. 26(2). 477–486. 124 indexed citations

18.

Dmello, Crismita, Sharada Sawant, Pratik R. Chaudhari, et al.. (2018). Aberrant expression of vimentin predisposes oral premalignant lesion derived cells towards transformation. Experimental and Molecular Pathology. 105(3). 243–251. 10 indexed citations

19.

Dmello, Crismita, Sharada Sawant, Hunain Alam, et al.. (2017). Vimentin regulates differentiation switch via modulation of keratin 14 levels and their expression together correlates with poor prognosis in oral cancer patients. PLoS ONE. 12(2). e0172559–e0172559. 34 indexed citations

20.

Dmello, Crismita, Sharada Sawant, Hunain Alam, et al.. (2015). Vimentin-mediated regulation of cell motility through modulation of beta4 integrin protein levels in oral tumor derived cells. The International Journal of Biochemistry & Cell Biology. 70. 161–172. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact